For research use only. Not for therapeutic Use.
ARD-2585（Cat No.:I044404）is a potent and selective degrader of the androgen receptor (AR), designed for targeted protein degradation via the PROTAC (proteolysis-targeting chimera) strategy. Developed to overcome resistance mechanisms in prostate cancer, particularly castration-resistant prostate cancer (CRPC), ARD-2585 induces ubiquitination and proteasomal degradation of AR, including its splice variants. This approach offers a distinct advantage over traditional AR antagonists by eliminating the receptor rather than merely inhibiting its activity. ARD-2585 shows promise in preclinical studies for reducing tumor growth and represents a novel therapeutic strategy in advanced prostate cancer treatment.
| CAS Number | 2757422-79-8 |
| Synonyms | N-[4-(3-chloro-4-cyano-N-methylanilino)cyclohexyl]-4-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]piperazin-1-yl]benzamide |
| Molecular Formula | C41H43ClN8O5 |
| Purity | ≥95% |
| IUPAC Name | N-[4-(3-chloro-4-cyano-N-methylanilino)cyclohexyl]-4-[4-[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]azetidin-3-yl]piperazin-1-yl]benzamide |
| InChI | InChI=1S/C41H43ClN8O5/c1-46(30-9-4-26(22-43)35(42)21-30)28-10-5-27(6-11-28)44-38(52)25-2-7-29(8-3-25)47-16-18-48(19-17-47)32-23-49(24-32)31-12-13-33-34(20-31)41(55)50(40(33)54)36-14-15-37(51)45-39(36)53/h2-4,7-9,12-13,20-21,27-28,32,36H,5-6,10-11,14-19,23-24H2,1H3,(H,44,52)(H,45,51,53) |
| InChIKey | LUCHABJUYSYJAT-UHFFFAOYSA-N |
| SMILES | CN(C1CCC(CC1)NC(=O)C2=CC=C(C=C2)N3CCN(CC3)C4CN(C4)C5=CC6=C(C=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)C8=CC(=C(C=C8)C#N)Cl |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
